Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies
| Autor: | Martine de Champvallins, Yuri Karpov, Csaba András Dézsi, Csaba Farsang, M G Glezer, Romualda Brzozowska-Villatte |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Population Blood Pressure Gastroenterology Internal medicine Diabetes mellitus Post-hoc analysis medicine Perindopril Humans Pharmacology (medical) Obesity education Perindopril/indapamide Antihypertensive Agents Original Research Aged Metabolic Syndrome education.field_of_study Type 2 diabetes mellitus business.industry Indapamide Single-pill combination General Medicine Middle Aged medicine.disease Drug Combinations Blood pressure Treatment Outcome Blood pressure control Diabetes Mellitus Type 2 Hypertension Metabolic syndrome business medicine.drug |
| Zdroj: | Advances in Therapy |
| ISSN: | 1865-8652 0741-238X |
| Popis: | Introduction To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS). Methods This post hoc analysis pooled raw data from four large observational studies (FORTISSIMO, FORSAGE, ACES, PICASSO). Patients, most with uncontrolled blood pressure (BP) on previous treatments were switched to Per/Ind (10 mg/2.5 mg) SPC at study entry. Office systolic and diastolic blood pressures (SBP and DBP) were measured at baseline, 1 month and 3 months. Results In the overall pooled population (N = 16,763), mean age was 61 ± 12 years, HT duration 11 ± 8 years, and baseline SBP/DBP 162/94 mmHg. T2DM, obesity and MetS were present in 21%, 49% and 27% of patients, respectively. Subgroups had similar mean age and HT duration to the overall population; patients with T2DM were slightly older (64 ± 10 years) with a longer HT duration (13 ± 8 years). Mean BP was approximately 160/95 mmHg in each subgroup. At 1 month, mean SBP decreased by approximately 20 mmHg in the overall population, and by a further 10 mmHg at 3 months. Similar results were observed in the three subgroups, with mean changes from baseline at 3 months of − 28 ± 15/− 13 ± 10 in T2DM; − 30 ± 15/− 14 ± 10 in obesity; and – 31 ± 15/− 15 ± 9 mmHg in MetS. BP decreases were greatest in patients with grade II or grade III HT. BP control rates ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink